828 related articles for article (PubMed ID: 26458124)
1. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D as an early predictor of multiple sclerosis activity and progression.
Ascherio A; Munger KL; White R; Köchert K; Simon KC; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Radü EW; Sandbrink R; Kappos L; Pohl C
JAMA Neurol; 2014 Mar; 71(3):306-14. PubMed ID: 24445558
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
5. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
Løken-Amsrud KI; Holmøy T; Bakke SJ; Beiske AG; Bjerve KS; Bjørnarå BT; Hovdal H; Lilleås F; Midgard R; Pedersen T; Benth JS; Sandvik L; Torkildsen O; Wergeland S; Myhr KM
Neurology; 2012 Jul; 79(3):267-73. PubMed ID: 22700809
[TBL] [Abstract][Full Text] [Related]
7. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
8. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.
Soilu-Hänninen M; Laaksonen M; Laitinen I; Erälinna JP; Lilius EM; Mononen I
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):152-7. PubMed ID: 17578859
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Zivadinov R; Qu J; Cookfair D; Duan X; Bang E; Bergsland N; Hussein S; Cherneva M; Willis L; Heininen-Brown M; Ramanathan M
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):189-95. PubMed ID: 21047880
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
11. The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
Zhang Y; Liu G; Han X; Dong H; Geng J
J Neuroimmunol; 2016 Aug; 297():127-31. PubMed ID: 27397085
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M; Munger KL; Martínez-Lapiscina EH; Barro C; Edan G; Freedman MS; Hartung HP; Montalbán X; Foley FW; Penner IK; Hemmer B; Fox EJ; Schippling S; Wicklein EM; Kappos L; Kuhle J; Ascherio A;
Neurology; 2020 May; 94(18):e1950-e1960. PubMed ID: 32300060
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.
Wergeland S; Myhr KM; Løken-Amsrud KI; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Kvistad SS; Holmøy T; Riise T; Torkildsen Ø
Eur J Neurol; 2016 Jun; 23(6):1064-70. PubMed ID: 26998820
[TBL] [Abstract][Full Text] [Related]
14. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
15. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
